CTOs on the Move

Indi Molecular

www.indimolecular.com

 
Indi Molecular provides PCCs for research and development in the fields for imaging agents for medical diagnostic imaging. Indi Imaging medical diagnostic research is provided to corporate partners, both as sponsored research or in partnership. Research and development using novel and custom PCCs, including PCCs that are membrane permeable, are provided for under the PCC Inside brand for uses that include antigen detection for both cell and tissue analysis, therapeutics or in vitro diagnostics.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Indi Molecular raised $11.5M on 06/29/2017

Similar Companies

Sesen Bio

We are passionate in our commitment to improving and renewing people`s lives. Sesen Bio is a late-stage company devWe are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company`s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.eloping fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body`s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium`s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors.

Plaxgen

Plaxgen is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glen Research Corporation

Glen Research Corporation is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tactiva Therapeutics

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.

Seattle Genetics

Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.